Kiromic Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 35

Employees

  • Stock Symbol
  • KRBP

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.91
  • (As of Wednesday Closing)

Kiromic General Information

Description

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Contact Information

Website
www.kiromic.com
Formerly Known As
Kiromic, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Fannin South Professional Building
  • 7707 Fannin Suite 140
  • Houston, TX 77054
  • United States
+1 (844)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PINX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Fannin South Professional Building
  • 7707 Fannin Suite 140
  • Houston, TX 77054
  • United States
+1 (844)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kiromic Stock Performance

As of 27-Nov-2024, Kiromic’s stock price is $0.91. Its current market cap is $1.41M with 1.55M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.91 $1.00 $0.18 - $3.78 $1.41M 1.55M 2.9K -$6.22

Kiromic Financials Summary

As of 30-Sep-2024, Kiromic has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 11,485 8,066 5,039 20,641
Revenue 0 0 0 0
EBITDA (19,287) (16,876) (32,891) (25,107)
Net Income (25,098) (20,949) (34,731) (25,589)
Total Assets 10,245 12,169 11,968 30,730
Total Debt 14,714 15,542 9,410 454
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kiromic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kiromic‘s full profile, request access.

Request a free trial

Kiromic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic ce
Drug Discovery
Houston, TX
35 As of 2023

Hayward, CA
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kiromic Competitors (11)

One of Kiromic’s 11 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arcus Biosciences Formerly VC-backed Hayward, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
RAPT Therapeutics Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 11 competitors. Get the full list »

Kiromic Patents

  • 32

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Kiromic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4333983-A1 Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof Pending 07-May-2021
US-20240293544-A1 Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof Pending 07-May-2021
CA-3202233-A1 Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules Pending 18-Nov-2020
EP-4248368-A1 Disease-associated isoform identifier Pending 18-Nov-2020
US-20230420077-A1 Disease-associated isoform identifier Pending 18-Nov-2020 G16B25/10
To view Kiromic’s complete patent history, request access »

Kiromic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kiromic Investments & Acquisitions (2)

Kiromic’s most recent deal was a Merger/Acquisition with In Silico Solutions for . The deal was made on 26-Jul-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
In Silico Solutions 26-Jul-2021 Merger/Acquisition Other Healthcare Technology Systems
Joint Venture (Kiromic Biopharma / Molipharma) 03-Apr-2020 Joint Venture Biotechnology
To view Kiromic’s complete investments and acquisitions history, request access »

Kiromic Subsidiaries (1)

Company Name Industry Location Founded
In Silico Solutions Other Healthcare Technology Systems Fairfax, VA
To view Kiromic’s complete subsidiaries history, request access »

Kiromic FAQs

  • When was Kiromic founded?

    Kiromic was founded in 2006.

  • Where is Kiromic headquartered?

    Kiromic is headquartered in Houston, TX.

  • What is the size of Kiromic?

    Kiromic has 35 total employees.

  • What industry is Kiromic in?

    Kiromic’s primary industry is Drug Discovery.

  • Is Kiromic a private or public company?

    Kiromic is a Public company.

  • What is Kiromic’s stock symbol?

    The ticker symbol for Kiromic is KRBP.

  • What is the current stock price of Kiromic?

    As of 27-Nov-2024 the stock price of Kiromic is $0.91.

  • What is the current market cap of Kiromic?

    The current market capitalization of Kiromic is $1.41M.

  • Who are Kiromic’s competitors?

    Arcus Biosciences, Kite Pharma, RAPT Therapeutics, Adaptimmune Therapeutics, and NexImmune are some of the 11 competitors of Kiromic.

  • What is Kiromic’s annual earnings per share (EPS)?

    Kiromic’s EPS for 12 months was -$6.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »